CHICAGO, November 9 - At The American Association for the Study of Liver Diseases
1998 Annual Meeting in Chicago, November 6 - 10, some of the world's top biomedical
researchers unveiled studies of drug therapies that are offering new hope in the
fight against Hepatitis B and C. Another study examined the role of a newly
discovered virus in liver disease.

HIV Drug Lamivudine Helps Hepatitis B Patients When Interferon Can't

At the AASLD Annual Meeting, Eugene Schiff, MD, University of Miami, discussed a study
of the effects of a new drug, Lamivudine, that was given to chronic Hepatitis B
patients who had previously failed Interferon therapy. There are many such patients,
because Interferon is effective only 30%-40% of the time. Lamivudine, a drug that has
been used to treat HIV patients, can be taken orally unlike Interferon, which must be
injected every day. The study found that patients who took Lamivudine did much better
than those who took a placebo, or who took Lamivudine in combination with Interferon.
All those who took the new drug alone depressed the level of Hepatitis B virus in
their bodies. Almost three quarters cleared the virus, either permanently or as long
as they kept taking the drug "All in all, Lamivudine appears safe and effective,"
said Schiff. "In the future, I expect it will be used in combination with other drugs
as part of an overall treatment of chronic Hepatitis B patients."

Interferon alfa-2b +ribavirin vs. Hepatitis C - Three Studies

Three studies on treatment of chronic Hepatitis C, reported at the AASLD Annual
Meeting, found that acombination of Interferon alfa-2b and ribavirin (Rebetol) was
dramatically effective.
John McHutchison, MD, of Scripps Clinic and Research Foundation, reported on one
study of more than 900 chronic Hepatitis C patients who had not had antiviral therapy
before. Half the patients were give'"/>

(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes Mr. ... global perspective to make an impact in a post pandemic world,” said Co-Chairman John ... director of the company. , “The Greffex board is excited to have Neil as ...

(Date:5/28/2020)... and FORT WORTH, Texas (PRWEB) , ... May ... ... stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 ... of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May ...

(Date:4/7/2020)... ... April 06, 2020 , ... Gateway Genomics , leading developer ... SneakPeek Early Gender DNA Tests sold in March, just months after attaining ... an ecommerce product, where a mom could order her kit online, collect a DNA ...

(Date:4/1/2020)... ... March 30, 2020 , ... Kinetic Vet, an animal ... EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the animal health industry, ... against microorganisms for up to 90 days. , In addition to reducing the ...

(Date:4/1/2020)... ... March 31, 2020 , ... Bedoukian Research, Inc. ... a Joint Development Agreement that builds on each company’s expertise in developing efficient ... in the supply of high-quality insect pheromones as well as flavors and fragrances. ...